person · Reporting owner
Fenimore Christopher R.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | EVP Finance CFO | August 18, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date August 18, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,984 |
Ending reported balance
After 2026-08-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-18 · Exercise / conversion · Acquired 6,283 · Balance 24,583 Row 2 · 2026-08-18 · Tax withholding · Disposed 4,599 · Balance 19,984 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $381.92 · Expires 2026-12-16 | Direct | 6,000 |
Reported balance
After 2026-08-18 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-18 · Exercise / conversion · Disposed 6,283 · Balance 6,000 F2: The stock option award vested in four equal annual installments, commencing one year after the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 1,574 |
Reported balance
Holding disclosure · report date 2026-08-18 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,574 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 1,897 |
Reported balance
Holding disclosure · report date 2026-08-18 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,897 F1: These shares are held in a trust for the benefit of the reporting person's spouse. The reporting person and the reporting person's spouse are trustees of the trust. |
| Common StockSEC Table I · non-derivative | Indirectby Trust for Daugh | 25 |
Reported balance
Holding disclosure · report date 2026-08-18 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 25 |
| Common StockSEC Table I · non-derivative | Indirectby Trust for Son | 25 |
Reported balance
Holding disclosure · report date 2026-08-18 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 25 |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are held in a trust for the benefit of the reporting person's spouse. The reporting person and the reporting person's spouse are trustees of the trust.
F2: The stock option award vested in four equal annual installments, commencing one year after the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 18, 2026 Filed Aug 20, 2026 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,283 | $0.00 Strike: $381.92 | $0.00 |
DisclosureSEC source: 0001697422-26-000002 · edgardoc.xml · derivative · entry 7 Fenimore Christopher R. · CIK 0001697422 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,283 shares Expires 2026-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award vested in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 4,599 | $813.47 | $3,741,148.53 |
DisclosureSEC source: 0001697422-26-000002 · edgardoc.xml · nonDerivative · entry 2 Fenimore Christopher R. · CIK 0001697422 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,984 Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 6,283 | $381.92 | $2,399,603.36 |
DisclosureSEC source: 0001697422-26-000002 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 992 | $712.94 | $707,236.48 |
DisclosureSEC source: 0001697422-25-000004 · edgardoc.xml · nonDerivative · entry 2 Fenimore Christopher R. · CIK 0001697422 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,300 Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 14,924 | $0.00 Strike: $726.71 | $0.00 |
DisclosureSEC source: 0001697422-25-000004 · edgardoc.xml · derivative · entry 7 Fenimore Christopher R. · CIK 0001697422 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,924 Underlying: Common Stock · 14,924 shares Expires 2035-12-05 F3 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 3,027 | $0.00 | $0.00 |
DisclosureSEC source: 0001697422-25-000004 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,292 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 5, 2027 and 50% on December 5, 2029. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 491 | $730.81 | $358,827.71 |
DisclosureSEC source: 0001883850-24-000061 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · SVP Finance & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,265 Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 1,140 | $787.00 | $897,180.00 |
DisclosureSEC source: 0001883850-24-000050 · edgardoc.xml · nonDerivative · entry 2 Fenimore Christopher R. · CIK 0001697422 · SVP Finance & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,756 Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 9,979 | $0.00 Strike: $771.64 | $0.00 |
DisclosureSEC source: 0001883850-24-000050 · edgardoc.xml · derivative · entry 7 Fenimore Christopher R. · CIK 0001697422 · SVP Finance & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,979 Underlying: Common Stock · 9,979 shares Expires 2034-12-06 F3 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 2,591 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-24-000050 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · SVP Finance & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,896 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 6, 2026 and 50% on December 6, 2028. Read SEC document |
| August 28, 2024 Filed Aug 29, 2024 20:27 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $1,206.67 | $241,334.00 |
DisclosureSEC source: 0001883850-24-000045 · edgardoc.xml · nonDerivative · entry 10 Fenimore Christopher R. · CIK 0001697422 · SVP Finance & CFO 10b5-1 filing: No plan indicated Ownership: Indirect · by Trust for Son Disclosed balance after: 25 F10 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on August 28, 2024 at prices ranging from $1,206.65 to $1,206.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 28, 2024 at each separate price. Read SEC document |
| August 28, 2024 Filed Aug 29, 2024 20:27 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 235 | $1,205.67 | $283,332.45 |
DisclosureSEC source: 0001883850-24-000045 · edgardoc.xml · nonDerivative · entry 9 Fenimore Christopher R. · CIK 0001697422 · SVP Finance & CFO 10b5-1 filing: No plan indicated Ownership: Indirect · by Trust for Son Disclosed balance after: 225 F9 · price: Represents volume-weighted average price of sales of 235 shares of Company stock on August 28, 2024 at prices ranging from $1,205.51 to $1,205.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 28, 2024 at each separate price. Read SEC document |
| August 28, 2024 Filed Aug 29, 2024 20:27 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $1,206.70 | $241,340.00 |
DisclosureSEC source: 0001883850-24-000045 · edgardoc.xml · nonDerivative · entry 8 Fenimore Christopher R. · CIK 0001697422 · SVP Finance & CFO 10b5-1 filing: No plan indicated Ownership: Indirect · by Trust for Daugh Disclosed balance after: 25 F8 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on August 28, 2024 at prices ranging from $1,206.66 to $1,206.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 28, 2024 at each separate price. Read SEC document |
| August 28, 2024 Filed Aug 29, 2024 20:27 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 236 | $1,205.67 | $284,538.12 |
DisclosureSEC source: 0001883850-24-000045 · edgardoc.xml · nonDerivative · entry 7 Fenimore Christopher R. · CIK 0001697422 · SVP Finance & CFO 10b5-1 filing: No plan indicated Ownership: Indirect · by Trust for Daugh Disclosed balance after: 225 F7 · price: Represents volume-weighted average price of sales of 236 shares of Company stock on August 28, 2024 at prices ranging from $1,205.51 to $1,205.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 28, 2024 at each separate price. Read SEC document |
| August 28, 2024 Filed Aug 29, 2024 20:27 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 450 | $1,206.15 | $542,767.50 |
DisclosureSEC source: 0001883850-24-000045 · edgardoc.xml · nonDerivative · entry 6 Fenimore Christopher R. · CIK 0001697422 · SVP Finance & CFO 10b5-1 filing: No plan indicated Ownership: Indirect · 2022 GRAT Disclosed balance after: 0 F6 · price: Represents volume-weighted average price of sales of 450 shares of Company stock on August 28, 2024 at prices ranging from $1,206.00 to $1,206.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 28, 2024 at each separate price. Read SEC document |
| August 28, 2024 Filed Aug 29, 2024 20:27 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 928 | $1,205.49 | $1,118,694.72 |
DisclosureSEC source: 0001883850-24-000045 · edgardoc.xml · nonDerivative · entry 5 Fenimore Christopher R. · CIK 0001697422 · SVP Finance & CFO 10b5-1 filing: No plan indicated Ownership: Indirect · 2022 GRAT Disclosed balance after: 450 F5 · price: Represents volume-weighted average price of sales of 928 shares of Company stock on August 28, 2024 at prices ranging from $1,205.00 to $1,205.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 28, 2024 at each separate price. Read SEC document |
| August 28, 2024 Filed Aug 29, 2024 20:27 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,237 | $1,204.71 | $2,694,936.27 |
DisclosureSEC source: 0001883850-24-000045 · edgardoc.xml · nonDerivative · entry 4 Fenimore Christopher R. · CIK 0001697422 · SVP Finance & CFO 10b5-1 filing: No plan indicated Ownership: Indirect · 2022 GRAT Disclosed balance after: 1,378 F4 · price: Represents volume-weighted average price of sales of 2,237 shares of Company stock on August 28, 2024 at prices ranging from $1,204.00 to $1,204.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 28, 2024 at each separate price. Read SEC document |
| August 28, 2024 Filed Aug 29, 2024 20:27 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $1,206.30 | $241,260.00 |
DisclosureSEC source: 0001883850-24-000045 · edgardoc.xml · nonDerivative · entry 3 Fenimore Christopher R. · CIK 0001697422 · SVP Finance & CFO 10b5-1 filing: No plan indicated Ownership: Indirect · 2021 GRAT Disclosed balance after: 0 F3 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on August 28, 2024 at prices ranging from $1,206.09 to $1,206.63. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 28, 2024 at each separate price. Read SEC document |
| August 28, 2024 Filed Aug 29, 2024 20:27 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 766 | $1,205.44 | $923,367.04 |
DisclosureSEC source: 0001883850-24-000045 · edgardoc.xml · nonDerivative · entry 2 Fenimore Christopher R. · CIK 0001697422 · SVP Finance & CFO 10b5-1 filing: No plan indicated Ownership: Indirect · 2021 GRAT Disclosed balance after: 200 F2 · price: Represents volume-weighted average price of sales of 766 shares of Company stock on August 28, 2024 at prices ranging from $1,205.02 to $1,205.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 28, 2024 at each separate price. Read SEC document |
| August 28, 2024 Filed Aug 29, 2024 20:27 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 228 | $1,204.79 | $274,692.12 |
DisclosureSEC source: 0001883850-24-000045 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · SVP Finance & CFO 10b5-1 filing: No plan indicated Ownership: Indirect · 2021 GRAT Disclosed balance after: 966 F1 · price: Represents volume-weighted average price of sales of 228 shares of Company stock on August 28, 2024 at prices ranging from $1,204.76 to $1,204.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 28, 2024 at each separate price. Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 600 | $955.00 | $573,000.00 |
DisclosureSEC source: 0001968202-24-000061 · edgardoc.xml · nonDerivative · entry 6 Fenimore Christopher R. · CIK 0001697422 · SVP Finance & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,372 Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,100 | $954.57 | $1,050,027.00 |
DisclosureSEC source: 0001968202-24-000061 · edgardoc.xml · nonDerivative · entry 5 Fenimore Christopher R. · CIK 0001697422 · SVP Finance & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,972 F5 · price: Represents volume-weighted average price of sales of 1,100 shares of Company stock on February 9, 2024 at prices ranging from $954.00 to $954.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2024 at each separate price. Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,342 | $953.47 | $1,279,556.74 |
DisclosureSEC source: 0001968202-24-000061 · edgardoc.xml · nonDerivative · entry 4 Fenimore Christopher R. · CIK 0001697422 · SVP Finance & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,072 F4 · price: Represents volume-weighted average price of sales of 1,342 shares of Company stock on February 9, 2024 at prices ranging from $953.02 to $953.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2024 at each separate price. Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,046 | $952.62 | $996,440.52 |
DisclosureSEC source: 0001968202-24-000061 · edgardoc.xml · nonDerivative · entry 3 Fenimore Christopher R. · CIK 0001697422 · SVP Finance & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,414 F3 · price: Represents volume-weighted average price of sales of 1,046 shares of Company stock on February 9, 2024 at prices ranging from $952.11 to $952.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2024 at each separate price. Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 487 | $951.39 | $463,326.93 |
DisclosureSEC source: 0001968202-24-000061 · edgardoc.xml · nonDerivative · entry 2 Fenimore Christopher R. · CIK 0001697422 · SVP Finance & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,460 F2 · price: Represents volume-weighted average price of sales of 487 shares of Company stock on February 9, 2024 at prices ranging from $951.03 to $951.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2024 at each separate price. Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 344 | $950.49 | $326,968.56 |
DisclosureSEC source: 0001968202-24-000061 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · SVP Finance & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,947 F1 · price: Represents volume-weighted average price of sales of 344 shares of Company stock on February 9, 2024 at prices ranging from $950.33 to $950.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2024 at each separate price. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 21:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $555.67 | $0.00 |
DisclosureSEC source: 0001968202-24-000041 · edgardoc.xml · derivative · entry 12 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2025-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 21:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $399.66 | $0.00 |
DisclosureSEC source: 0001968202-24-000041 · edgardoc.xml · derivative · entry 11 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2024-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 21:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 3,583 | $948.50 | $3,398,475.50 |
DisclosureSEC source: 0001968202-24-000041 · edgardoc.xml · nonDerivative · entry 4 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,291 Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 21:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 5,000 | $399.66 | $1,998,300.00 |
DisclosureSEC source: 0001968202-24-000041 · edgardoc.xml · nonDerivative · entry 3 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 21:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 3,986 | $948.50 | $3,780,721.00 |
DisclosureSEC source: 0001968202-24-000041 · edgardoc.xml · nonDerivative · entry 2 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,874 Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 21:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 5,000 | $555.67 | $2,778,350.00 |
DisclosureSEC source: 0001968202-24-000041 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,860 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 21:22 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $555.67 | $0.00 |
DisclosureSEC source: 0001883850-24-000008 · edgardoc.xml · derivative · entry 12 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2025-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 21:22 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $399.66 | $0.00 |
DisclosureSEC source: 0001883850-24-000008 · edgardoc.xml · derivative · entry 11 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2024-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 21:22 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 3,469 | $912.30 | $3,164,768.70 |
DisclosureSEC source: 0001883850-24-000008 · edgardoc.xml · nonDerivative · entry 4 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,860 Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 21:22 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 5,000 | $399.66 | $1,998,300.00 |
DisclosureSEC source: 0001883850-24-000008 · edgardoc.xml · nonDerivative · entry 3 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 21:22 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 4,043 | $912.30 | $3,688,428.90 |
DisclosureSEC source: 0001883850-24-000008 · edgardoc.xml · nonDerivative · entry 2 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,329 Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 21:22 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 5,000 | $555.67 | $2,778,350.00 |
DisclosureSEC source: 0001883850-24-000008 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,372 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,448 | $856.71 | $2,097,226.08 |
DisclosureSEC source: 0001883850-23-000107 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,372 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 25, 2023. Read SEC document |
| December 22, 2023 Filed Dec 26, 2023 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 250 | $846.27 | $211,567.50 |
DisclosureSEC source: 0001883850-23-000103 · edgardoc.xml · nonDerivative · entry 3 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,820 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 25, 2023. Read SEC document |
| December 21, 2023 Filed Dec 26, 2023 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,224 | $844.09 | $1,033,166.16 |
DisclosureSEC source: 0001883850-23-000103 · edgardoc.xml · nonDerivative · entry 2 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,070 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 25, 2023. Read SEC document |
| December 21, 2023 Filed Dec 26, 2023 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 456 | $843.79 | $384,768.24 |
DisclosureSEC source: 0001883850-23-000103 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,294 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 25, 2023. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 2,552 | $856.71 | $2,186,323.92 |
DisclosureSEC source: 0001883850-23-000101 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,750 Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 260 | $844.09 | $219,463.40 |
DisclosureSEC source: 0001968202-23-000050 · edgardoc.xml · nonDerivative · entry 4 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,302 Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 1,276 | $844.09 | $1,077,058.84 |
DisclosureSEC source: 0001968202-23-000050 · edgardoc.xml · nonDerivative · entry 3 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,562 Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 8,499 | $0.00 Strike: $843.79 | $0.00 |
DisclosureSEC source: 0001968202-23-000050 · edgardoc.xml · derivative · entry 11 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,499 Underlying: Common Stock · 8,499 shares Expires 2033-12-08 F3 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 2,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001968202-23-000050 · edgardoc.xml · nonDerivative · entry 2 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,838 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 8, 2025 and 50% on December 8, 2027. Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 474 | $843.79 | $399,956.46 |
DisclosureSEC source: 0001968202-23-000050 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,468 Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $399.66 | $0.00 |
DisclosureSEC source: 0001968202-23-000031 · edgardoc.xml · derivative · entry 9 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 7,000 shares Expires 2024-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 5,198 | $842.66 | $4,380,146.68 |
DisclosureSEC source: 0001968202-23-000031 · edgardoc.xml · nonDerivative · entry 2 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,942 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.